In situ use of suicide genes for therapy of brain tumours

Annals of Medicine

Volumn 31, Issue 6, 1999, Pages 421-429

  Wildner, Oliver ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Brain tumours; Bystander; Ganciclovir; Gene therapy; Herpes simplex virus; Thymidine kinase; Vector producing cells; Viral vectors

Indexed keywords

GANCICLOVIR; PRODRUG; THYMIDINE KINASE;

ADENOVIRUS; BRAIN CANCER; CYTOTOXICITY; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SUICIDE GENE; TUMOR CELL; TUMOR VOLUME;

EID: 0033374374     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899908998799     Document Type: Review

References (75)

1. Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER Jr, Peace BB. National survey of patterns of care for brain-tumor patients. J Neurosurg 1989; 71: 826-36.
2. Mao Y, Desmeules M, Semenciw RM, Hill G, Gaudette L, Wigle DT. Increasing brain cancer rates in Canada. Can Med Assoc J 1991; 145: 1583-91.
3. Posner JB. Brain metastases: 1995. A brief review. J Neurooncol 1996; 27: 287-93.
4. Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 1987; 21: 607-14.
5. Yamada M, Shimizu K, Miyao Y, Hayakawa T, Nakajima K, Nakahira K, et al. Migration of genetically labeled glioma cells after implantation into murine brain. J Neurosci Res 1994; 38: 415-23.
6. Kikuchi K, Neuwelt EA. Presence of immunosuppressive factors in brain-tumor cyst fluid. J Neurosurg 1983; 59: 790-9.
7. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-81.
8. Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980; 255: 7204-7.
9. Ilsley DD, Lee SH, Miller WH, Kuchta RD. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry 1995; 34: 2504-10.
10. Thust R, Schacke M, Wutzler P. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Antiviral Res 1996; 31: 105-13.
11. Haynes P, Lambert TR, Mitchell ID. Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Mutat Res 1996; 369: 65-74.
12. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A 1977; 74: 5716-20.
13. Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994; 48: 455-84.
14. Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 589-93.
15. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-83.
16. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-2.
17. Colombo BM, Benedetti S, Ottolenghi S, Mora M, Pollo B, Poli G, et al. The 'bystander effect': association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-72.
18. Elshami AA, Saavedra A, Zhang H, Kucharczcuk JC, Spray DC, Fishman GI, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3: 85-92.
19. Dilber MS, Abedi MR, Christensson B, Björkstrand B, Kidder GM, Naus CC, et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997; 57: 1523-8.
20. Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 1994; 91: 4348-52.
21. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-34.
22. Ram Z, Culver KW, Oshiro EM, Viola JJ, De Vroom HL, Otto E, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354-61.
23. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9: 1083-92.
24. Spector SA, Weingeist T, Pollard RB, Dieterich DT, Samo T, Benson CA, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis 1993; 168: 557-63.
25. Morris JC, Ramsey WJ, Wildner O, Musslow H, Aguilar-Cordova E, Blaese RM. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther (in press).
26. Elshami AA, Cook JW, Amin KM, Choi H, Park JY, Coonrod L, et al. The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. Cancer Gene Ther 1997; 4: 213-21.
27. Touraine RL, Vahanian N, Ramsey WJ, Blaese RM. Enhancement of the herpes simplex virus thymidine kinase/ ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther 1998; 9: 2385-91.
28. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A 1996; 93: 3525-9.
29. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997; 4: 222-8.
30. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-33.
31. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of HSV-tk. Cancer Res 1999; 59: 410-3.
32. Wildner O, Morris JC, Vahanian NN, Ford HJ, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6: 57-62.
33. Kim JH, Kim SH, Brown SL, Freytag SO. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 1994; 54: 6053-6.
34. Wildner O, Blaese RM, Candotti F. Enzyme prodrug gene therapy: synergistic use of the HSV-tk/GCV system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res 1999; 59: 5233-8.
35. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-26.
36. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 1994; 54: 1503-6.
37. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-80.
38. Uckert W, Kammertons T, Haack K, Quin Z, Gebert J, Schendel DJ, et al. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 1998; 9: 855-65.
39. Grignet-Debrus C, Calberg-Bacq CM. Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Ther 1997; 4: 560-9.
40. Besnard C, Monthioux E, Jami J. Selection against expression of the Escherichia coli gene gpt in hprt+ mouse teratocarcinoma and hybrid cells. Mol Cell Biol 1987; 7: 4139-41.
41. Mulligan RC, Berg P. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc Natl Acad Sci U S A 1981; 78: 2072-6.
42. Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997; 4: 229-38.
43. Hughes BW, Wells AH, Bebok Z, Gadi VK, Garver RJ Jr, Parker WB, et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 1995; 55: 3339-45.
44. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther 1997; 8: 709-17.
45. Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, et al. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther 1998; 9: 1261-73.
46. Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, et al. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci U S A 1995; 92: 9829-33.
47. Doran SE, Ren XD, Betz AL, Pagel MA, Neuwelt EA, Roessler BJ, et al. Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption. Neurosurgery 1995; 36: 965-70.
48. Barnett FH, Rainov NG, Ikeda K, Schuback DE, Elliott P, Kramm CM, et al. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther 1999; 6: 14-20.
49. Vandier D, Rixe O, Brenner M, Gouyette A, Besnard F. Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res 1998; 58: 4577-80.
50. Spear MA, Herrlinger U, Rainov N, Pechan P, Weissleder R, Breakefield XO. Targeting gene therapy vectors to CNS malignancies. J Neurovirol 1998; 4: 133-47.
51. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-6.
52. Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994; 68: 8001-7.
53. Kantoff PW, Kohn DB, Mitsuya H, Armentano D, Sieberg M, Zwiebel JA, et al. Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1986; 83: 6563-7.
54. Miller AD. Retroviral vectors. Curr Top Microbiol Immunol 1992; 158: 1-24.
55. Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992; 33: 493-503.
56. Short MP, Choi BC, Lee JK, Malick A, Breakefield XO, Martuza RL. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990; 27: 427-39.
57. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980-6, 989.
58. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4: 39-69.
59. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998; 9: 2595-604.
60. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
61. Le Gal La Salle G, Robert JJ, Berrard S, Ridoux V, Stratford-Perricaudet LD, Perricaudet M, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988-90.
62. Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, et al. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 1993; 3: 224-8.
63. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1994; 91: 3054-7.
64. Perez-Cruet MJ, Trask TW, Chen SH, Goodman JC, Woo SL, Grossman RG, et al. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 1994; 39: 506-11.
65. Wood MJ, Charlton HM, Wood KJ, Kajiwara K, Byrnes AP. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci 1996; 19: 497-501.
66. Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA. Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol 1998; 4: 194-203.
67. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91: 4407-11.
68. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-5.
69. Driesse MJ, Vincent AJ, Sillevis Smitt PA, Kros JM, Hoogerbrugge PM, Avezaat CJ, et al. Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: toxicity study in nonhuman primates. Gene Ther 1998; 5: 1122-9.
70. Dion LD, Goldsmith KT, Strong TV, Bilbao G, Curiel DT, Garver RIJ. E1A RNA transcripts amplify adenovirus-mediated tumor reduction. Gene Ther 1996; 3: 1021-5.
71. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597-603.
72. Glorioso JC, Goins WF, Meaney CA, Fink DJ, DeLuca NA. Gene transfer to brain using herpes simplex virus vectors. Ann Neurol 1994; 35 Suppl: S28-S34.
73. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-6.
74. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-6.
75. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 1997; 4: 222-8.